<p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）的股票在週一由 Citizens Jmp 的研究分析師重新發布了 “市場表現優於大盤” 的評級，Benzinga 報道。他們目前對該股票的目標價格為 7.00 美元，低於之前的 10.00 美元目標價格。Citizens Jmp 的價格目標指向該股票當前價格的潛在上漲幅度為 105.28%。</p>
<p>MDXG 已經成為其他多份報告的主題。瑞銀集團在 2 月 23 日的報告中對 MiMedx Group 的股票設定了 10.00 美元的目標價格。華爾街 Zen 在 2 月 28 日的報告中將 MiMedx Group 的股票評級從 “強力買入” 下調至 “買入”。Cantor Fitzgerald 在 2 月 17 日的報告中將 MiMedx Group 的股票目標價格從 12.00 美元下調至 8.00 美元，並對該股票給予了 “超配” 評級。Craig Hallum 在週五的報告中將 MiMedx Group 的股票目標價格從 10.00 美元下調至 7.00 美元，並對該股票給予了 “買入” 評級。最後，花旗集團在 2 月 23 日的報告中開始覆蓋 MiMedx Group 的股票，並對該股票給予了 “市場表現優於大盤” 的評級。六位分析師對該股票給予了買入評級，一位分析師給予了持有評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價格為 8.67 美元。</p>
<p><strong>查看我們對 MiMedx Group 的最新分析</strong></p>
<h2>MiMedx Group 股票表現</h2>
<p>納斯達克 MDXG 的股票在週一開盤價為 3.41 美元。該公司的債務與股本比率為 0.06，速動比率為 3.92，流動比率為 4.32。該公司的市值為 5.0662 億美元，市盈率為 10.66，貝塔值為 1.65。該公司的 50 日移動平均線為 4.46 美元，200 日移動平均線為 5.85 美元。MiMedx Group 的 52 周低點為 3.31 美元，52 周高點為 7.99 美元。</p>
<p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）最後一次公佈季度財報是在 2 月 25 日，報告顯示該季度每股收益（EPS）為 0.14 美元，超出分析師的共識預期 0.09 美元，超出幅度為 0.05 美元。MiMedx Group 的淨利潤率為 11.60%，股本回報率為 29.37%。該季度的收入為 1.181 億美元，而共識預期為 1.0678 億美元。整體來看，分析師預計 MiMedx Group 在當前財年將發佈 0.3 美元的每股收益。</p>
<h2>機構投資者對 MiMedx Group 的看法</h2>
<p>幾家大型投資者最近增加或減少了對該股票的持股。先鋒集團在第四季度將其在 MiMedx Group 的持股增加了 5.6%。先鋒集團目前擁有 7184262 股該公司的股票，價值 48637000 美元，在此期間又購買了 382623 股。道富集團在第四季度將其在 MiMedx Group 的持股增加了 6.1%。道富集團目前擁有 3813796 股該公司的股票，價值 25819000 美元，在此期間又購買了 219190 股。First Light Asset Management LLC 在第三季度將其在 MiMedx Group 的持股增加了 89.5%。First Light Asset Management LLC 目前擁有 3652952 股該公司的股票，價值 25498000 美元，在此期間又購買了 1725458 股。Dimensional Fund Advisors LP 在第四季度將其在 MiMedx Group 的持股增加了 4.1%。Dimensional Fund Advisors LP 目前擁有 2479369 股該公司的股票，價值 16786000 美元，在此期間又購買了 97036 股。最後，Renaissance Technologies LLC 在第四季度將其在 MiMedx Group 的持股增加了 22.8%。Renaissance Technologies LLC 目前擁有 2467065 股該公司的股票，價值 16702000 美元，在此期間又購買了 458838 股。79.15% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 MiMedx Group</h2>
<p>（獲取免費報告）</p>
<p>MiMedx Group, Inc 是一家生物製藥公司，專注於開發、製造和營銷源自人類胎盤組織的再生生物材料產品。該公司的核心使命是利用羊膜和絨毛膜中的細胞外基質和生長因子來支持傷口癒合和外科應用。MiMedx 的產品線利用專有的純化工藝，旨在保留原生組織特性，同時確保無菌和安全。</p>
<p>MiMedx 的主要產品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/絨毛膜同種異體移植物，適用於急性和慢性傷口的治療，包括糖尿病足潰瘍、靜脈性腿部潰瘍和手術部位修復。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比 MiMedx Group 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 MiMedx Group 嗎？</h2>
<p>在你考慮 MiMedx Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 MiMedx Group 並不在名單上。</p>
<p>雖然 MiMedx Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MDXG

<p>Citizens Jmp 重申了對 MiMedx Group (NASDAQ:MDXG) 的 “市場跑贏大盤” 評級，調整後的目標價為 7.00 美元，低於之前的 10.00 美元。這個目標價暗示從當前股價來看有 105.28% 的潛在上漲空間。其他分析師也調整了對 MiMedx Group 的評級和目標價，普遍評級為 “適度買入”，平均目標價為 8.67 美元。該公司報告的季度每股收益為 0.14 美元，超出預期，市值為 5.0662 億美元</p>

<p>MiMedx Group (NASDAQ:MDXG - Get Free Report)'s stock had its &#34;market outperform&#34; rating reissued by research analysts at Citizens Jmp in a research note issued to investors on Monday,Benzinga reports. They currently have a $7.00 target price on the stock, down from their prior target price of $10.00. Citizens Jmp's price objective points to a potential upside of 105.28% from the stock's current price.</p>
<div class="lb-trans"><p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）的股票在週一由 Citizens Jmp 的研究分析師重新發布了 “市場表現優於大盤” 的評級，Benzinga 報道。他們目前對該股票的目標價格為 7.00 美元，低於之前的 10.00 美元目標價格。Citizens Jmp 的價格目標指向該股票當前價格的潛在上漲幅度為 105.28%。</p>
</div><p>MDXG has been the topic of a number of other reports. UBS Group set a $10.00 target price on shares of MiMedx Group in a report on Monday, February 23rd. Wall Street Zen downgraded shares of MiMedx Group from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, February 28th. Cantor Fitzgerald reduced their target price on shares of MiMedx Group from $12.00 to $8.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, February 17th. Craig Hallum reduced their target price on shares of MiMedx Group from $10.00 to $7.00 and set a &#34;buy&#34; rating on the stock in a report on Friday. Finally, Citigroup started coverage on shares of MiMedx Group in a report on Monday, February 23rd. They issued a &#34;market outperform&#34; rating on the stock. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $8.67.</p>
<div class="lb-trans"><p>MDXG 已經成為其他多份報告的主題。瑞銀集團在 2 月 23 日的報告中對 MiMedx Group 的股票設定了 10.00 美元的目標價格。華爾街 Zen 在 2 月 28 日的報告中將 MiMedx Group 的股票評級從 “強力買入” 下調至 “買入”。Cantor Fitzgerald 在 2 月 17 日的報告中將 MiMedx Group 的股票目標價格從 12.00 美元下調至 8.00 美元，並對該股票給予了 “超配” 評級。Craig Hallum 在週五的報告中將 MiMedx Group 的股票目標價格從 10.00 美元下調至 7.00 美元，並對該股票給予了 “買入” 評級。最後，花旗集團在 2 月 23 日的報告中開始覆蓋 MiMedx Group 的股票，並對該股票給予了 “市場表現優於大盤” 的評級。六位分析師對該股票給予了買入評級，一位分析師給予了持有評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價格為 8.67 美元。</p>
</div><p><strong>View Our Latest Analysis on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>查看我們對 MiMedx Group 的最新分析</strong></p>
</div><h2>MiMedx Group Stock Performance</h2>
<div class="lb-trans"><h2>MiMedx Group 股票表現</h2>
</div><p>Shares of NASDAQ MDXG opened at $3.41 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.92 and a current ratio of 4.32. The company has a market cap of $506.62 million, a P/E ratio of 10.66 and a beta of 1.65. The firm's fifty day moving average is $4.46 and its two-hundred day moving average is $5.85. MiMedx Group has a 52-week low of $3.31 and a 52-week high of $7.99.</p>
<div class="lb-trans"><p>納斯達克 MDXG 的股票在週一開盤價為 3.41 美元。該公司的債務與股本比率為 0.06，速動比率為 3.92，流動比率為 4.32。該公司的市值為 5.0662 億美元，市盈率為 10.66，貝塔值為 1.65。該公司的 50 日移動平均線為 4.46 美元，200 日移動平均線為 5.85 美元。MiMedx Group 的 52 周低點為 3.31 美元，52 周高點為 7.99 美元。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. The company had revenue of $118.10 million for the quarter, compared to the consensus estimate of $106.78 million. As a group, analysts anticipate that MiMedx Group will post 0.3 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）最後一次公佈季度財報是在 2 月 25 日，報告顯示該季度每股收益（EPS）為 0.14 美元，超出分析師的共識預期 0.09 美元，超出幅度為 0.05 美元。MiMedx Group 的淨利潤率為 11.60%，股本回報率為 29.37%。該季度的收入為 1.181 億美元，而共識預期為 1.0678 億美元。整體來看，分析師預計 MiMedx Group 在當前財年將發佈 0.3 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On MiMedx Group</h2>
<div class="lb-trans"><h2>機構投資者對 MiMedx Group 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company's stock valued at $48,637,000 after buying an additional 382,623 shares during the period. State Street Corp boosted its position in MiMedx Group by 6.1% in the 4th quarter. State Street Corp now owns 3,813,796 shares of the company's stock valued at $25,819,000 after buying an additional 219,190 shares during the period. First Light Asset Management LLC boosted its position in MiMedx Group by 89.5% in the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company's stock valued at $25,498,000 after buying an additional 1,725,458 shares during the period. Dimensional Fund Advisors LP boosted its position in MiMedx Group by 4.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,479,369 shares of the company's stock valued at $16,786,000 after buying an additional 97,036 shares during the period. Finally, Renaissance Technologies LLC boosted its position in MiMedx Group by 22.8% in the 4th quarter. Renaissance Technologies LLC now owns 2,467,065 shares of the company's stock valued at $16,702,000 after buying an additional 458,838 shares during the period. 79.15% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對該股票的持股。先鋒集團在第四季度將其在 MiMedx Group 的持股增加了 5.6%。先鋒集團目前擁有 7184262 股該公司的股票，價值 48637000 美元，在此期間又購買了 382623 股。道富集團在第四季度將其在 MiMedx Group 的持股增加了 6.1%。道富集團目前擁有 3813796 股該公司的股票，價值 25819000 美元，在此期間又購買了 219190 股。First Light Asset Management LLC 在第三季度將其在 MiMedx Group 的持股增加了 89.5%。First Light Asset Management LLC 目前擁有 3652952 股該公司的股票，價值 25498000 美元，在此期間又購買了 1725458 股。Dimensional Fund Advisors LP 在第四季度將其在 MiMedx Group 的持股增加了 4.1%。Dimensional Fund Advisors LP 目前擁有 2479369 股該公司的股票，價值 16786000 美元，在此期間又購買了 97036 股。最後，Renaissance Technologies LLC 在第四季度將其在 MiMedx Group 的持股增加了 22.8%。Renaissance Technologies LLC 目前擁有 2467065 股該公司的股票，價值 16702000 美元，在此期間又購買了 458838 股。79.15% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About MiMedx Group</h2>
<div class="lb-trans"><h2>關於 MiMedx Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物製藥公司，專注於開發、製造和營銷源自人類胎盤組織的再生生物材料產品。該公司的核心使命是利用羊膜和絨毛膜中的細胞外基質和生長因子來支持傷口癒合和外科應用。MiMedx 的產品線利用專有的純化工藝，旨在保留原生組織特性，同時確保無菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要產品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/絨毛膜同種異體移植物，適用於急性和慢性傷口的治療，包括糖尿病足潰瘍、靜脈性腿部潰瘍和手術部位修復。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 MiMedx Group 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 MiMedx Group 嗎？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MiMedx Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 MiMedx Group 並不在名單上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MiMedx Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Citizens Jmp 重申對 MiMedx Group（NASDAQ:MDXG）的 “市場表現優異” 評級